TPI 1100

Drug Profile

TPI 1100

Alternative Names: PD 3 project; PXS TPI 1100; TPI-PD3 project

Latest Information Update: 01 Apr 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Topigen Pharmaceuticals
  • Developer Pharmaxis; Topigen Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Phosphoric diester hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Chronic obstructive pulmonary disease

Most Recent Events

  • 09 Feb 2010 Topigen Pharmaceuticals has been acquired and merged into Pharmaxis
  • 15 Jul 2008 Phase-I clinical trials in Chronic obstructive pulmonary disease in North America (Inhalation)
  • 16 Dec 2004 Preclinical trials in Chronic obstructive pulmonary disease in Canada (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top